The Cooper Companies, Inc.
COO Healthcare · Medical Instruments & SuppliesFairly valued.
Fairly Valued (Neutral) — Filing.fyi's reading derived from the latest 10-K and forensic scores.
What the filing actually says.
The Cooper Companies’ most recent 10-Q presents a concise narrative, with its Management’s Discussion and Analysis (MD&A) explicitly stating, “There have been no material changes in our policies from those previously discussed in our Form 10-K” for the prior fiscal year. This brevity contrasts with the reported financial performance for the three months ended January 31, 2026, which shows net sales increasing to $1,024.1 million from $964.7 million in the prior year period. Gross profit also saw an increase, reaching $695.2 million compared to $660.2 million, culminating in operating income of $212.8 million, up from $182.0 million.
The forensic accounting models for this filing are not available, which means the quantitative signals typically derived from these tools remain uncalculated. For instance, Beneish’s 1999 eight-ratio earnings-manipulation detector, which flags accounting choices that might inflate earnings, cannot be applied. Similarly, Altman’s Z″ — a 1968 bankruptcy-distress index that assesses a company’s likelihood of financial failure — is absent. Piotroski’s F-Score, a 9-point fundamental strength scan, which evaluates profitability, leverage, liquidity, and operating efficiency, is also not provided. The Fog Index — a readability score where 12 equals a newspaper and 18+ is obfuscatory — is likewise unavailable.
Item 7 of the MD&A does, however, address market risks, noting that the company is “exposed to market risks that relate principally to changes in interest rates and foreign currency fluctuations.” It further clarifies the company’s approach to managing these exposures, stating, “We do not enter into derivative financial instrument transactions for speculative purposes.” This explicit statement indicates a conservative stance on financial instruments, suggesting that any use of derivatives would be for hedging rather than for generating profits from market movements.
This filing provides a snapshot of recent operational performance and a clear statement on risk management policy. However, the absence of calculated forensic scores means the document alone cannot offer the structured quantitative insights into potential earnings manipulation, bankruptcy risk, or fundamental strength that such models provide. Consequently, a comprehensive assessment of whether the security is mispriced requires additional analysis beyond the scope of this quarterly report.
Filing timeline
- May 4, 20268-KMaterial event (2026-05-04)No specific items found in 8-K.0Read →
- Apr 8, 20268-KMaterial event (2026-04-07)No specific items found in 8-K.0Read →
- Mar 6, 202610-QQuarterly report (2026-01-31)Period: 2026-01-310Read →
- Mar 5, 20268-KMaterial event (2026-03-05)No specific items found in 8-K.0Read →
- Feb 24, 2026DEF 14AProxy statement (2026-04-07)0Read →
- Dec 5, 202510-KAnnual report (2025-10-31)Period: 2025-10-310Read →
If this case caught your eye
Financial Shenanigans
Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.
View on Amazon →The Interpretation of Financial Statements
The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.
View on Amazon →Quality of Earnings
Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.
View on Amazon →